慢性心不全：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 23
3.2 Prognosis 27
3.3 Quality of Life 27
3.4 Symptoms 28
4 Epidemiology 30
4.1 Risk Factors and Comorbidities 30
4.1.1 Age and sex are highly associated with the risk of chronic heart failure 32
4.1.2 History of cardiovascular disease increases the risk of developing chronic heart failure 32
4.1.3 Unhealthy lifestyles increase the risk of chronic heart failure 33
4.1.4 People with diabetes mellitus are twice as likely to develop chronic heart failure 33
4.1.5 Nearly 20% of patients with chronic kidney disease develop chronic heart failure 34
4.1.6 Comorbidities 34
4.1.7 Prognosis for chronic heart failure remains poor 35
4.2 Global Trends 36
4.2.1 United States 36
4.2.2 France 37
4.2.3 Germany 38
4.2.4 Italy 38
4.2.5 Spain 38
4.2.6 United Kingdom 39
4.2.7 Japan 39
4.2.8 China 40
4.3 Forecast Methodology 40
4.3.1 Sources Used 40
4.3.2 Forecast Assumptions and Methods 45
4.3.3 Forecast Assumptions and Methods for New York Heart Association Class Distributions 48
4.3.4 Sources Not Used 49
4.4 Epidemiology Forecast (2012-2022) 49
4.4.1 Prevalent Cases of Chronic Heart Failure 49
4.4.2 Age-Specific Prevalent Cases 52
4.4.3 Sex-Specific Prevalent Cases 54
4.4.4 Age-Standardized Prevalence 59
4.4.5 New York Heart Association Class Distributions 61
4.5 Discussion 62
4.5.1 Limitations of Analysis 64
4.5.2 Strengths of Analysis 64
5 Disease Management 65
5.1 Treatment Overview 66
5.1.1 Pharmacological Treatments 68
5.1.2 Mechanical Devices 74
5.2 US 75
5.2.1 Diagnosis and Referral Patterns 75
5.2.2 Clinical Practice 76
5.3 France 77
5.3.1 Diagnosis and Referral Patterns 77
5.3.2 Clinical Practice 78
5.4 Germany 80
5.4.1 Diagnosis and Referral Patterns 80
5.4.2 Clinical Practice 80
5.5 Italy 82
5.5.1 Diagnosis and Referral Patterns 82
5.5.2 Clinical Practice 82
5.6 Spain 84
5.6.1 Diagnosis and Referral Patterns 84
5.6.2 Clinical Practice 85
5.7 UK 87
5.7.1 Diagnosis and Referral Patterns 87
5.7.2 Clinical Practice 88
5.8 Japan 90
5.8.1 Diagnosis and Referral Patterns 90
5.8.2 Clinical Practice 90
6 Competitive Assessment 92
6.1 Overview 92
6.2 Strategic Competitor Assessment 92
6.3 Drug Profiles 95
6.3.1 Angiotensin-Converting Enzyme (ACE) Inhibitors 95
6.3.2 Diuretics 98
6.3.3 Angiotensin Receptor Blockers 100
6.3.4 Beta Blockers 113
6.3.5 Procoralan (ivabradine) 125
6.3.6 Mineralocorticoid Receptor Antagonists 129
6.3.7 Digoxin 132
7 Opportunity and Unmet Need 135
7.1 Overview 135
7.2 Lack of Therapies for HF-PEF Patients 136
7.3 Lack of Therapies for Patients with Renal Impairment 137
7.4 Diagnosis of Asymptomatic Left Ventricular Dysfunction 137
7.5 Treatment of Patients with Multiple Comorbidities 138
7.6 Increase in Survival of CHF Patients 138
7.7 Unmet Needs Gap Analysis 139
7.8 Opportunity: Treatment of Patients with HF-PEF 140
7.9 Opportunity: Therapies for Patients with Renal Impairment and Multiple Comorbidities 140
7.10 Opportunity: New Drugs that Show Increase in Survival of CHF Patients 140
8 Pipeline Assessment 141
8.1 Overview 141
8.1.1 Clinical Trials by Country 142
8.2 Clinical Trials by Phase and Trial Status 143
8.3 Promising Drugs in Clinical Development 144
8.3.1 LCZ-696 145
8.3.2 Tekturna (aliskiren) 151
8.3.3 Neucardin (rhNRG-1) 155
8.4 Innovative Early-Stage Approaches 159
8.4.1 BAY 94-8862 159
8.4.2 Omecamtiv mecarbil 162
8.5 Promising Non-Pharmacological Approaches 165
8.5.1 MyoCell 166
8.5.2 C-Cure (C3BS-CQR-1) 171
8.5.3 Mydicar (rAAV1-SERCA2a) 174
9 Current and Future Players 179
9.1 Overview 179
9.2 Trends in Corporate Strategy 180
9.3 Company Profiles 181
9.3.1 Novartis 181
10 Market Outlook 185
10.1 Global Markets 185
10.1.1 Forecast 185
10.1.2 Drivers and Barriers – Global Issues 188
10.2 United States 191
10.2.1 Forecast 191
10.2.2 Key Events 195
10.2.3 Drivers and Barriers 195
10.3 France 197
10.3.1 Forecast 197
10.3.2 Key Events 200
10.3.3 Drivers and Barriers 200
10.4 Germany 201
10.4.1 Forecast 201
10.4.2 Key Events 204
10.4.3 Drivers and Barriers 204
10.5 Italy 205
10.5.1 Forecast 205
10.5.2 Key Events 207
10.5.3 Drivers and Barriers 208
10.6 Spain 209
10.6.1 Forecast 209
10.6.2 Key Events 211
10.6.3 Drivers and Barriers 212
10.7 United Kingdom 213
10.7.1 Forecast 213
10.7.2 Key Events 216
10.7.3 Drivers and Barriers 216
10.8 Japan 217
10.8.1 Forecast 217
10.8.2 Key Events 220
10.8.3 Drivers and Barriers 220
11 Appendix 223
11.1 Bibliography 223
11.2 Abbreviations 240
11.3 Methodology 244
11.4 Forecasting Methodology 244
11.4.1 NYHA Class Segmentation of Total Prevalent CHF Population 244
11.4.2 Diagnosed CHF Population 245
11.4.3 Drug-Treated CHF Population 246
11.4.4 Patient Population Breakdown: HF-REF versus HF-PEF 246
11.4.5 Treatment of HF-REF versus HF-PEF 246
11.4.6 Drugs Included in Each Therapeutic Class 247
11.4.7 Launch and Patent Expiry Dates 247
11.4.8 General Pricing Assumptions 248
11.4.9 Drugs Assumptions 249
11.4.10 Generic Erosion 254
11.4.11 Pricing of Pipeline Agents 254
11.5 Physicians and Specialists Included in this Study 255
11.6 Survey of Prescribing Physicians 256
11.7 About the Authors 257
11.7.1 Author 257
11.7.2 Epidemiologist 257
11.7.3 Global Head of Healthcare 258
11.8 About GlobalData 259